Leeward Investments LLC MA Sells 16,903 Shares of Hologic, Inc. (NASDAQ:HOLX)

Leeward Investments LLC MA lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,395 shares of the medical equipment provider's stock after selling 16,903 shares during the quarter. Leeward Investments LLC MA owned 0.06% of Hologic worth $11,600,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Wolff Wiese Magana LLC bought a new position in Hologic in the third quarter valued at approximately $25,000. Innealta Capital LLC bought a new stake in Hologic in the 2nd quarter valued at $25,000. iA Global Asset Management Inc. bought a new position in Hologic during the 1st quarter worth about $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic in the 2nd quarter valued at about $37,000. Finally, Cromwell Holdings LLC lifted its holdings in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday. StockNews.com lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Wednesday. Raymond James raised their target price on shares of Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Finally, Stephens restated an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $89.25.

Hologic Stock Performance

Shares of HOLX traded down $1.20 during trading hours on Thursday, hitting $79.29. The company had a trading volume of 1,456,026 shares, compared to its average volume of 1,594,685. The business has a fifty day moving average of $81.05 and a 200-day moving average of $78.12. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The firm has a market cap of $18.42 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98. Hologic, Inc. has a 12 month low of $66.93 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The firm had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The business's revenue was up 4.5% on a year-over-year basis. Equities analysts anticipate that Hologic, Inc. will post 4.36 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.